PDF(Sci-hub)
Abstract：
The treatment of invasive fungal infections remains a challenge, both for the diagnosis and for the need of providing the appropriate antifungal therapy. Candida auris is a pathogenic yeast that is responsible for hospital outbreaks, especially in intensive care units; it is characterized by a high resistance to the antifungal agents and can become multidrug-resistant. At present, the recommended antifungal agents for the invasive infections with this pathogen are echinocandins, always after carrying out an antifungal susceptibility testing. In case of no clinical response or persistent candidemia, the addition of liposomal amphotericin B or isavuconazole may be considered. Both fungal infection of the central nervous system and that associated with biomedical devices remain rare entities affecting mainly immunocompromised patients. However, an increase in their incidence in recent years, along with high morbidity and mortality, has been shown. The treatment of these infections is conditioned by the limited knowledge of the pharmacokinetic properties of antifungals. A better understanding of the pharmacokinetic and pharmacodynamic parameters of the different antifungals is essential to determine the efficacy of the antifungal agents in the treatment of these infections.
摘要：
侵袭性真菌感染的治疗仍然是一个挑战。诊断和需要提供适当的抗真菌治疗。耳念珠菌是一种致病酵母，是医院爆发的原因，特别是在重症监护病房;它的特点是对抗真菌药物的高耐药性，并可能成为多重耐药。目前,这种病原体侵袭性感染的推荐抗真菌药物是棘白菌素，总是在进行抗真菌药敏试验后.在没有临床反应或持续念珠菌菌血症的情况下，可以考虑加入两性霉素B脂质体或异阿武康唑.中枢神经系统的真菌感染和与生物医学设备相关的真菌感染仍然是罕见的实体，主要影响免疫功能低下的患者。然而,近年来发病率增加，伴随着高发病率和死亡率，已显示。这些感染的治疗取决于对抗真菌药的药代动力学特性的有限了解。更好地了解不同抗真菌剂的药代动力学和药效学参数对于确定抗真菌剂在治疗这些感染中的功效至关重要。
